Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1990;17(3):194–202.

Systemic Antifungal Agents

Layne O Gentry 1
PMCID: PMC324917  PMID: 15227171

Full text

PDF
194

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arndt C. A., Walsh T. J., McCully C. L., Balis F. M., Pizzo P. A., Poplack D. G. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J Infect Dis. 1988 Jan;157(1):178–180. doi: 10.1093/infdis/157.1.178. [DOI] [PubMed] [Google Scholar]
  2. Athar M. A., Winner H. I. The development of resistance by candida species to polyene antibiotics in vitro. J Med Microbiol. 1971 Nov;4(4):505–517. doi: 10.1099/00222615-4-4-505. [DOI] [PubMed] [Google Scholar]
  3. BUTLER W. T., BENNETT J. E., ALLING D. W., WERTLAKE P. T., UTZ J. P., HILL G. J., 2nd NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS. Ann Intern Med. 1964 Aug;61:175–187. doi: 10.7326/0003-4819-61-2-175. [DOI] [PubMed] [Google Scholar]
  4. Barnert J., Behr W., Reich H. An amphotericin B-resistant case of rhinocerebral mucor mycosis. Infection. 1985 May-Jun;13(3):134–136. doi: 10.1007/BF01642873. [DOI] [PubMed] [Google Scholar]
  5. Bennet J. E. Flucytosine. Ann Intern Med. 1977 Mar;86(3):319–321. doi: 10.7326/0003-4819-86-3-319. [DOI] [PubMed] [Google Scholar]
  6. Bennett J. E., Dismukes W. E., Duma R. J., Medoff G., Sande M. A., Gallis H., Leonard J., Fields B. T., Bradshaw M., Haywood H. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979 Jul 19;301(3):126–131. doi: 10.1056/NEJM197907193010303. [DOI] [PubMed] [Google Scholar]
  7. Bindschadler D. D., Bennett J. E. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis. 1969 Oct;120(4):427–436. doi: 10.1093/infdis/120.4.427. [DOI] [PubMed] [Google Scholar]
  8. Block E. R., Bennett J. E., Livoti L. G., Klein W. J., Jr, MacGregor R. R., Henderson L. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Ann Intern Med. 1974 May;80(5):613–617. doi: 10.7326/0003-4819-80-5-613. [DOI] [PubMed] [Google Scholar]
  9. Branch R. A. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med. 1988 Nov;148(11):2389–2394. [PubMed] [Google Scholar]
  10. Christiansen K. J., Bernard E. M., Gold J. W., Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985 Nov;152(5):1037–1043. doi: 10.1093/infdis/152.5.1037. [DOI] [PubMed] [Google Scholar]
  11. Cohen J. Treatment of systemic yeast infection with fluconazole. J Antimicrob Chemother. 1989 Feb;23(2):294–295. doi: 10.1093/jac/23.2.294. [DOI] [PubMed] [Google Scholar]
  12. Collette N., van der Auwera P., Lopez A. P., Heymans C., Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989 Mar;33(3):362–368. doi: 10.1128/aac.33.3.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Conti D. J., Tolkoff-Rubin N. E., Baker G. P., Jr, Doran M., Cosimi A. B., Delmonico F., Auchincloss H., Jr, Russell P. S., Rubin R. H. Successful treatment of invasive fungal infection with fluconazole in organ transplant recipients. Transplantation. 1989 Oct;48(4):692–695. [PubMed] [Google Scholar]
  14. Craven P. C., Graybill J. R., Jorgensen J. H., Dismukes W. E., Levine B. E. High-dose ketoconazole for treatment of fungal infections of the central nervous system. Ann Intern Med. 1983 Feb;98(2):160–167. doi: 10.7326/0003-4819-98-2-160. [DOI] [PubMed] [Google Scholar]
  15. Daneshmend T. K., Warnock D. W. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet. 1983 Jan-Feb;8(1):17–42. doi: 10.2165/00003088-198308010-00002. [DOI] [PubMed] [Google Scholar]
  16. De Beule K., De Doncker P., Cauwenbergh G., Koster M., Legendre R., Blatchford N., Daunas J., Chwetzoff E. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses. 1988 Sep;31(9):476–485. doi: 10.1111/j.1439-0507.1988.tb03653.x. [DOI] [PubMed] [Google Scholar]
  17. Denning D. W., Tucker R. M., Hanson L. H., Hamilton J. R., Stevens D. A. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med. 1989 Oct;149(10):2301–2308. [PubMed] [Google Scholar]
  18. Denning D. W., Tucker R. M., Hanson L. H., Stevens D. A. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989 Jun;86(6 Pt 2):791–800. doi: 10.1016/0002-9343(89)90475-0. [DOI] [PubMed] [Google Scholar]
  19. Dismukes W. E., Cloud G., Gallis H. A., Kerkering T. M., Medoff G., Craven P. C., Kaplowitz L. G., Fisher J. F., Gregg C. R., Bowles C. A. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med. 1987 Aug 6;317(6):334–341. doi: 10.1056/NEJM198708063170602. [DOI] [PubMed] [Google Scholar]
  20. Duarte P. A., Chow C. C., Simmons F., Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med. 1984 May;144(5):1069–1070. [PubMed] [Google Scholar]
  21. Eisenberg R. S., Oatway W. H. Nebulization of amphotericin B. Am Rev Respir Dis. 1971 Feb;103(2):289–292. doi: 10.1164/arrd.1971.103.2.289. [DOI] [PubMed] [Google Scholar]
  22. Elliott J. A., Milne L. J., Cumming D. Chronic necrotising pulmonary aspergillosis treated with itraconazole. Thorax. 1989 Oct;44(10):820–821. doi: 10.1136/thx.44.10.820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Faggian G., Livi U., Bortolotti U., Mazzucco A., Stellin G., Chiominto B., Vivani M. A., Gallucci V. Itraconazole therapy for acute invasive pulmonary aspergillosis in heart transplantation. Transplant Proc. 1989 Feb;21(1 Pt 3):2506–2507. [PubMed] [Google Scholar]
  24. Fainstein V., Bodey G. P., Elting L., Maksymiuk A., Keating M., McCredie K. B. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother. 1987 Jan;31(1):11–15. doi: 10.1128/aac.31.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gallis H. A., Drew R. H., Pickard W. W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990 Mar-Apr;12(2):308–329. doi: 10.1093/clinids/12.2.308. [DOI] [PubMed] [Google Scholar]
  26. Graybill J. R. New antifungal agents. Eur J Clin Microbiol Infect Dis. 1989 May;8(5):402–412. doi: 10.1007/BF01964056. [DOI] [PubMed] [Google Scholar]
  27. Graybill J. R. Systemic fungal infections: diagnosis and treatment. I. Therapeutic agents. Infect Dis Clin North Am. 1988 Dec;2(4):805–825. [PubMed] [Google Scholar]
  28. Hay R. J. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S334–S337. doi: 10.1093/clinids/12.supplement_3.s334. [DOI] [PubMed] [Google Scholar]
  29. Hermans P. E., Keys T. F. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc. 1983 Apr;58(4):223–231. [PubMed] [Google Scholar]
  30. Ismail M. A., Lerner S. A. Disseminated blastomycosis in a pregnant woman: review of amphotericin B usage during pregnancy. Am Rev Respir Dis. 1982 Aug;126(2):350–353. doi: 10.1164/arrd.1982.126.2.350. [DOI] [PubMed] [Google Scholar]
  31. Johnson P. C., Khardori N., Najjar A. F., Butt F., Mansell P. W., Sarosi G. A. Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Aug;85(2):152–158. doi: 10.1016/s0002-9343(88)80334-6. [DOI] [PubMed] [Google Scholar]
  32. Johnson R. J., Blair A. D., Ahmad S. Ketoconazole kinetics in chronic peritoneal dialysis. Clin Pharmacol Ther. 1985 Mar;37(3):325–329. doi: 10.1038/clpt.1985.47. [DOI] [PubMed] [Google Scholar]
  33. Kennedy M. S., Deeg H. J., Siegel M., Crowley J. J., Storb R., Thomas E. D. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation. 1983 Mar;35(3):211–215. doi: 10.1097/00007890-198303000-00005. [DOI] [PubMed] [Google Scholar]
  34. Kwan J. T., Foxall P. J., Davidson D. G., Bending M. R., Eisinger A. J. Interaction of cyclosporin and itraconazole. Lancet. 1987 Aug 1;2(8553):282–282. doi: 10.1016/s0140-6736(87)90873-7. [DOI] [PubMed] [Google Scholar]
  35. LOURIA D. B. Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antibiotic Med Clin Ther (New York) 1958 May;5(5):295–301. [PubMed] [Google Scholar]
  36. Lechi A., Montesi G., Dean P., Pancera P., Arosio E. Ketoconazole: clinical evaluation in severe fungal infections. Chemioterapia. 1986 Feb;5(1):18–22. [PubMed] [Google Scholar]
  37. Lee J. W., Lin C., Loebenberg D., Rubin M., Pizzo P. A., Walsh T. J. Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother. 1989 Nov;33(11):1932–1935. doi: 10.1128/aac.33.11.1932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Levine J., Bernard D. B., Idelson B. A., Farnham H., Saunders C., Sugar A. M. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: successful treatment with fluconazole, a new orally active antifungal agent. Am J Med. 1989 Jun;86(6 Pt 2):825–827. doi: 10.1016/0002-9343(89)90481-6. [DOI] [PubMed] [Google Scholar]
  39. Lopez-Berestein G., Bodey G. P., Fainstein V., Keating M., Frankel L. S., Zeluff B., Gentry L., Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989 Nov;149(11):2533–2536. [PubMed] [Google Scholar]
  40. Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr;151(4):704–710. doi: 10.1093/infdis/151.4.704. [DOI] [PubMed] [Google Scholar]
  41. Lopez-Berestein G., Mehta R., Hopfer R. L., Mills K., Kasi L., Mehta K., Fainstein V., Luna M., Hersh E. M., Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983 May;147(5):939–945. doi: 10.1093/infdis/147.5.939. [DOI] [PubMed] [Google Scholar]
  42. Maksymiuk A. W., Thongprasert S., Hopfer R., Luna M., Fainstein V., Bodey G. P. Systemic candidiasis in cancer patients. Am J Med. 1984 Oct 30;77(4D):20–27. [PubMed] [Google Scholar]
  43. Medoff G., Dismukes W. E., Meade R. H., 3rd, Moses J. M. A new therapeutic approach to Candida infections. A preliminary report. Arch Intern Med. 1972 Aug;130(2):241–245. [PubMed] [Google Scholar]
  44. Meunier-Carpentier F. Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of fungal infections. Am J Med. 1984 Apr;76(4):652–656. doi: 10.1016/0002-9343(84)90290-0. [DOI] [PubMed] [Google Scholar]
  45. Meunier F., Lambert C., Van der Auwera P. In-vitro activity of SCH39304 in comparison with amphotericin B and fluconazole. J Antimicrob Chemother. 1990 Feb;25(2):227–236. doi: 10.1093/jac/25.2.227. [DOI] [PubMed] [Google Scholar]
  46. Morgan D. J., Ching M. S., Raymond K., Bury R. W., Mashford M. L., Kong B., Sabto J., Gurr F. W., Somogyi A. A. Elimination of amphotericin B in impaired renal function. Clin Pharmacol Ther. 1983 Aug;34(2):248–253. doi: 10.1038/clpt.1983.161. [DOI] [PubMed] [Google Scholar]
  47. Nováková I., Donnelly P., de Witte T., de Pauw B., Boezeman J., Veltman G. Itraconazole and cyclosporin nephrotoxicity. Lancet. 1987 Oct 17;2(8564):920–921. doi: 10.1016/s0140-6736(87)91412-7. [DOI] [PubMed] [Google Scholar]
  48. O'Day D. M., Head W. S., Robinson R. D., Stern W. H., Freeman J. M. Intraocular penetration of systemically administered antifungal agents. Curr Eye Res. 1985 Feb;4(2):131–134. doi: 10.3109/02713688508999978. [DOI] [PubMed] [Google Scholar]
  49. Odds F. C. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother. 1982 Nov;22(5):763–770. doi: 10.1128/aac.22.5.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Paladino J. A., Crass R. E. Amphotericin B and flucytosine in the treatment of candidal cystitis. Clin Pharm. 1982 Jul-Aug;1(4):349–352. [PubMed] [Google Scholar]
  51. Pennington J. E., Block E. R., Reynolds H. Y. 5-fluorocytosine and amphotericin B in bronchial secretions. Antimicrob Agents Chemother. 1974 Sep;6(3):324–326. doi: 10.1128/aac.6.3.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Perfect J. R., Durack D. T. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother. 1985 Jul;16(1):81–86. doi: 10.1093/jac/16.1.81. [DOI] [PubMed] [Google Scholar]
  53. Polsky B., Depman M. R., Gold J. W., Galicich J. H., Armstrong D. Intraventricular therapy of cryptococcal meningitis via a subcutaneous reservoir. Am J Med. 1986 Jul;81(1):24–28. doi: 10.1016/0002-9343(86)90177-4. [DOI] [PubMed] [Google Scholar]
  54. Price M. F., Gentry L. O. Incidence and significance of candida antigen in low-risk and high-risk patient populations. Eur J Clin Microbiol. 1986 Aug;5(4):416–419. doi: 10.1007/BF02075697. [DOI] [PubMed] [Google Scholar]
  55. Robinson P. A., Knirsch A. K., Joseph J. A. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S349–S363. doi: 10.1093/clinids/12.supplement_3.s349. [DOI] [PubMed] [Google Scholar]
  56. Salaki J. S., Louria D. B., Chmel H. Fungal and yeast infections of the central nervous system. A clinical review. Medicine (Baltimore) 1984 Mar;63(2):108–132. doi: 10.1097/00005792-198403000-00004. [DOI] [PubMed] [Google Scholar]
  57. Schaffner A., Frick P. G. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis. 1985 May;151(5):902–910. doi: 10.1093/infdis/151.5.902. [DOI] [PubMed] [Google Scholar]
  58. Seidenfeld S. M., Cooper B. H., Smith J. W., Luby J. P., Mackowiak P. A. Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species. J Infect Dis. 1983 Jan;147(1):116–119. doi: 10.1093/infdis/147.1.116. [DOI] [PubMed] [Google Scholar]
  59. Smego R. A., Jr, Perfect J. R., Durack D. T. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis. 1984 Nov-Dec;6(6):791–801. doi: 10.1093/clinids/6.6.791. [DOI] [PubMed] [Google Scholar]
  60. Stamm A. M., Diasio R. B., Dismukes W. E., Shadomy S., Cloud G. A., Bowles C. A., Karam G. H., Espinel-Ingroff A. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987 Aug;83(2):236–242. doi: 10.1016/0002-9343(87)90691-7. [DOI] [PubMed] [Google Scholar]
  61. Stamm A. M., Dismukes W. E. Current therapy of pulmonary and disseminated fungal diseases. Chest. 1983 Jun;83(6):911–917. doi: 10.1378/chest.83.6.911. [DOI] [PubMed] [Google Scholar]
  62. Stein D. K., Sugar A. M. Fungal infections in the immunocompromised host. Diagn Microbiol Infect Dis. 1989 Jul-Aug;12(4 Suppl):221S–228S. doi: 10.1016/0732-8893(89)90140-5. [DOI] [PubMed] [Google Scholar]
  63. Stern G. A., Fetkenhour C. L., O'Grady R. B. Intravitreal amphotericin B treatment of Candida endophthamitis. Arch Ophthalmol. 1977 Jan;95(1):89–93. doi: 10.1001/archopht.1977.04450010089008. [DOI] [PubMed] [Google Scholar]
  64. Stern J. J., Hartman B. J., Sharkey P., Rowland V., Squires K. E., Murray H. W., Graybill J. R. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med. 1988 Oct;85(4):477–480. doi: 10.1016/s0002-9343(88)80081-0. [DOI] [PubMed] [Google Scholar]
  65. Sugar A. M., Alsip S. G., Galgiani J. N., Graybill J. R., Dismukes W. E., Cloud G. A., Craven P. C., Stevens D. A. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother. 1987 Dec;31(12):1874–1878. doi: 10.1128/aac.31.12.1874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Sugar A. M., Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Oct;85(4):481–489. doi: 10.1016/s0002-9343(88)80082-2. [DOI] [PubMed] [Google Scholar]
  67. Tucker R. M., Denning D. W., Dupont B., Stevens D. A. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med. 1990 Jan 15;112(2):108–112. doi: 10.7326/0003-4819-112-2-108. [DOI] [PubMed] [Google Scholar]
  68. Van Tyle J. H. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984 Nov-Dec;4(6):343–373. doi: 10.1002/j.1875-9114.1984.tb03398.x. [DOI] [PubMed] [Google Scholar]
  69. Zuger A., Louie E., Holzman R. S., Simberkoff M. S., Rahal J. J. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med. 1986 Feb;104(2):234–240. doi: 10.7326/0003-4819-104-2-234. [DOI] [PubMed] [Google Scholar]
  70. de Gans J., Eeftinck Schattenkerk J. K., van Ketel R. J. Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome. Br Med J (Clin Res Ed) 1988 Jan 30;296(6618):339–339. doi: 10.1136/bmj.296.6618.339. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES